
    
      The drug being tested in this study was ixazomib. Ixazomib was tested to treat adult Asian
      people who had relapsed and/or refractory multiple myeloma.

      The study enrolled 43 patients. Participants were enrolled to receive:

        -  Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg.

      All participants were asked to take ixazomib capsules orally on Days 1, 8, and 15;
      lenalidomide capsules, orally, on Days 1 through 21; and dexamethasone tablets, orally, on
      Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or
      unacceptable toxicity (up to 20 cycles).

      This multi-center trial was conducted in Singapore, Hong Kong and South Korea. The overall
      time to participate in this study was up to 577 days. Participants made multiple visits to
      the clinic, and were contacted 30 days after last dose of study drug for a follow-up
      assessment.
    
  